These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37081405)

  • 1. Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States.
    Starling AJ; Kymes S; Asher D; Soni-Brahmbhatt S; Karnik-Henry M
    BMC Neurol; 2023 Apr; 23(1):158. PubMed ID: 37081405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Marmura MJ; Diener HC; Cowan RP; Tepper SJ; Diamond ML; Starling AJ; Hirman J; Mehta L; Brevig T; Cady R
    Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies.
    Pozo-Rosich P; Dodick DW; Ettrup A; Hirman J; Cady R
    BMC Neurol; 2022 Oct; 22(1):394. PubMed ID: 36284281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
    Winner PK; McAllister P; Chakhava G; Ailani J; Ettrup A; Krog Josiassen M; Lindsten A; Mehta L; Cady R
    JAMA; 2021 Jun; 325(23):2348-2356. PubMed ID: 34128999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Diener HC; Marmura MJ; Tepper SJ; Cowan R; Starling AJ; Diamond ML; Hirman J; Mehta L; Brevig T; Sperling B; Cady R
    Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab.
    Blumenfeld A; Ettrup A; Hirman J; Ebert B; Cady R
    BMC Neurol; 2022 Jul; 22(1):251. PubMed ID: 35804294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world prospective observational study of eptinezumab in Asian patients with migraine.
    Zhao YJ; Ong JJY; Sonu SK; Dang J; Ng CC; Herr KJ; Bose R; Jion YI
    Headache; 2024; 64(7):810-824. PubMed ID: 38785386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
    Ashina M; Tepper SJ; Gendolla A; Sperling B; Ettrup A; Josiassen MK; Starling AJ
    J Headache Pain; 2023 Nov; 24(1):155. PubMed ID: 37985968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
    McAllister P; Winner PK; Ailani J; Buse DC; Lipton RB; Chakhava G; Josiassen MK; Lindsten A; Mehta L; Ettrup A; Cady R
    J Headache Pain; 2022 Feb; 23(1):22. PubMed ID: 35130832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.
    Yu S; Zhou J; Luo G; Xiao Z; Ettrup A; Jansson G; Florea I; Ranc K; Pozo-Rosich P
    BMC Neurol; 2023 Dec; 23(1):441. PubMed ID: 38102535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
    Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
    Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
    Barbanti P; Goadsby PJ; Lambru G; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
    J Headache Pain; 2022 Dec; 23(1):153. PubMed ID: 36460983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
    Silberstein S; Diamond M; Hindiyeh NA; Biondi DM; Cady R; Hirman J; Allan B; Pederson S; Schaeffler B; Smith J
    J Headache Pain; 2020 Oct; 21(1):120. PubMed ID: 33023473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache.
    Blumenfeld A; Kudrow D; McAllister P; Boserup LP; Hirman J; Cady R
    Headache; 2024; 64(7):738-749. PubMed ID: 38924044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
    Lipton RB; Dodick DW; Ailani J; McGill L; Hirman J; Cady R
    Headache; 2021 May; 61(5):766-776. PubMed ID: 34013992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
    Ashina M; Lanteri-Minet M; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B; Pozo-Rosich P
    Cephalalgia; 2023 May; 43(5):3331024231170807. PubMed ID: 37125484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.
    Cowan RP; Marmura MJ; Diener HC; Starling AJ; Schim J; Hirman J; Brevig T; Cady R
    J Headache Pain; 2022 Sep; 23(1):115. PubMed ID: 36068494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study.
    Cady R; Lipton RB; Buse DC; Josiassen MK; Lindsten A; Ettrup A
    J Headache Pain; 2022 Jul; 23(1):91. PubMed ID: 35902796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study.
    Smith TR; Janelidze M; Chakhava G; Cady R; Hirman J; Allan B; Pederson S; Smith J; Schaeffler B
    Clin Ther; 2020 Dec; 42(12):2254-2265.e3. PubMed ID: 33250209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
    Ailani J; McAllister P; Winner PK; Chakhava G; Krog Josiassen M; Lindsten A; Sperling B; Ettrup A; Cady R
    BMC Neurol; 2022 Jun; 22(1):205. PubMed ID: 35659622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.